First-line antituberculosis drug.
Efficient presentation of an effective antituberculosis drug.
Drug administration by intravenous infusion provides 100 % bioavailability and maximum concentrations in blood and tissues.
This ensures the highest effectiveness of treatment and minimizes the risk of pathogen resistance.
The drug can be inhaled.
- Concentrate for infusion solution 30 mg/ml.
- 5 ml, 15 ml and 20 ml vials (150 mg, 450 mg and 600 mg of rifamycin).
- 15 ml and 20 ml vials (450 mg and 600 mg of rifamycin), solvent included.
Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Ukraine.